The Journal of Urology
Volume 181, Issue 3 , Pages 1361-1371 , March 2009

Response of Bladder Carcinoma Cells to TRAIL and Antisense Oligonucleotide, Bcl-2 or Clusterin Treatments

  • Bo Sun

      Affiliations

    • Department of Surgery, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Jacob A. Moibi

      Affiliations

    • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Allan Mak

      Affiliations

    • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Zhengwen Xiao

      Affiliations

    • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Wilson Roa

      Affiliations

    • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • ,
  • Ronald B. Moore

      Affiliations

    • Department of Surgery, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    • Corresponding Author InformationCorrespondence: Department of Surgery, University of Alberta, 2D2.16 Walter Mackenzie Health Sciences Centre, 8440 112 St., Edmonton, Alberta, Canada T6G 2B7 (telephone: 780-407-6330; FAX: 780-407-6331)
    • Financial interest and/or other relationship with Quest Pharmatech and Nat Immune.

Received 18 July 2008

References 

  1. Taylor JH, Davis J, Schellhammer P. Long-term follow-up of intravesical bacillus Calmette-Guerin treatment for superficial transitional-cell carcinoma of the bladder involving prostatic urethra. Clin Genitourin Cancer. 2007;5:386
  2. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 2004;64:3386
  3. McKnight JJ, Gray SB, O'Kane HF, Johnston SR, Williamson KE. Apoptosis and chemotherapy for bladder cancer. J Urol. 2005;173:683
  4. Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, et al. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther. 2007;6:2938
  5. Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, et al. Overexpression of Bcl2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun. 2001;280:788
  6. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol. 1996;155:316
  7. Sintich SM, Steinberg J, Kozlowski JM, Lee C, Pruden S, Sayeed S, et al. Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate. 1999;39:87
  8. Brown D, Kang S, Gryaznov S, DeDionisio L, Heidenreich O, Sullivan S, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem. 1994;269:26801
  9. Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem. 2007;282:28960
  10. Gazzaniga P, Gradilone A, Vercillo R, Gandini O, Silvestri I, Napolitano M, et al. bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer. 1996;69:100
  11. Jain D, Srinivasan R, Patel FD, Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol. 2003;88:22
  12. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997;3:1823
  13. Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Letters. 2000;471:93
  14. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL and TNF-α in human multiple myeloma cells is not blocked by Bcl-2. Cytokine. 1999;11:1010
  15. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 2002;21:2283
  16. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-κB Activation and NF-κB-regulated gene products through modulation of p65 and IκBα kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem. 2006;281:17023
  17. Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006;66:8731
  18. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell. 2005;8:5
  19. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7:909
  20. Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs. 2006;15:507

 Supported by the Canadian Cancer Society through National Cancer Institute of Canada Grant 15105.

PII: S0022-5347(08)02996-0

doi: 10.1016/j.juro.2008.10.148

The Journal of Urology
Volume 181, Issue 3 , Pages 1361-1371 , March 2009

Article Tools

* Image Usage & Resolution